A cDNA clone coding for a human brain protein (HuD), which is highly homologous to the Drosophila
neuronal determination protein Elav and elicits antibody formation in a high proportion of patients with paraneoplastic encephalomyelitis, was used to isolate a λ phage recombinant clone, including a large fragment of the relevant human genomic region. The fragment proved to be an efficient probe for the precise subregional mapping of the gene by molecular in situ hybridization onto extended human prometaphase chromosomes. Analysis of banded metaphases with clear hybridization signals pointed unequivocally to the localization of the HuD gene to human chromosome band 1p34.
Request reprints from Dr. Marcello Siniscalco, Imperial Cancer Research Fund, Room A5, PO Box 123, Lincoln’s Inn Fields, London WC2A 3PX (UK); telephone: 44-71-269-3053; fax: 44-71-269-3479.
Received: 5 April 1993
Published online: May 14, 2008
Number of Print Pages : 2
Cytogenetic and Genome Research
Vol. 65, No. 3, Year 1994 (Cover Date: 1994)
Journal Editor: Schmid M. (Würzburg)
ISSN: 1424–8581 (Print), eISSN: 1424–859X (Online)
For additional information: http://www.karger.com/CGR
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.